Irritable Bowel Syndrome Treatment Market Report by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2025-2033

Irritable Bowel Syndrome Treatment Market Report by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A4297

Market Overview:

The global irritable bowel syndrome treatment market size reached USD 2.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.7 Billion by 2033, exhibiting a growth rate (CAGR) of 7.8% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 2.9 Billion
Market Forecast in 2033
USD 5.7 Billion
Market Growth Rate 2025-2033 7.8%


Irritable bowel syndrome (IBS) refers to a chronic medical condition that affects the large intestine. It is usually caused by severe infection, stressful lifestyle, changes in gut microbes, muscle contractions in the intestine, and abnormalities in the nervous system. It can be characterized by gas, diarrhea, cramping, bloating, constipation, weight loss, vomiting, abdominal pain, and difficulty in swallowing. Several medications are currently available to relieve mild symptoms of IBS, including rifaximin, loperamide, laxatives, antispasmodics, fiber supplements, and coated peppermint oil capsules. Doctors also recommend probiotics and mental health therapies, such as cognitive behavioral-therapy (CBT), gut-directed hypnotherapy, and relaxation training, to treat certain patients.

Irritable Bowel Syndrome Treatment Market Trends:

Several factors increase the risk of IBS diseases, including food intolerances or sensitivities, bacterial infections in the digestive tract, small intestinal bacterial overgrowth, and mental disorders like anxiety, depression, and somatic symptom. This, along with improving diagnostic modalities and easy access to healthcare services, represents one of the key factors bolstering the growth of the market. Furthermore, IBS is one of the most common functional gastrointestinal disorders among the elderly. In confluence with this, the rising geriatric population across the globe is influencing the market positively. Besides this, several clinical trials, such as fecal microbiota transplantation (FMT), are being conducted to improve the treatment of IBS, which is contributing to market growth. In addition to this, as part of the Sustainable Development Goals (SDGs), governing agencies of various countries have pledged to substantially increase spending on research and development (R&D) projects and the number of researchers by 2030. This, in turn, is projected to expand the number of potential treatment options for IBS in the future.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global irritable bowel syndrome treatment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, product and distribution channel.

Breakup by Type:

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS
     

Breakup by Product:

  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Others
     

Breakup by Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores
     

Breakup by Region:

Irritable Bowel Syndrome Treatment Market Report

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Allergan plc (AbbVie Inc.), Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, Bausch Health Companies Inc., GlaxoSmithKline Plc, Novartis AG, Sebela Pharmaceuticals Inc., Synthetic Biologics Inc. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units  Billion USD
Segment Coverage Type, Product, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Allergan plc (AbbVie Inc.), Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, Bausch Health Companies Inc., GlaxoSmithKline Plc, Novartis AG, Sebela Pharmaceuticals Inc., Synthetic Biologics Inc., Takeda Pharmaceutical Company Limited
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the global irritable bowel syndrome treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global irritable bowel syndrome treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global irritable bowel syndrome treatment market and who are the key players?
  • What is the degree of competition in the industry?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Irritable Bowel Syndrome Treatment Market Report by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials